论文部分内容阅读
临床研究证明,可逆性转录酶抑制剂双脱氧胞苷(Dideoncytidine,ddC),是一个有效的抗人免疫缺陷病毒-1(HIV-1)的治疗药。治疗后可见循环中HIV-1P24抗原水平下降,CD_4~+淋巴细胞数增加;但能引起重度的剂量相关性神经病。小剂量ddC相关毒性有报告15例服ddC0.005mg/kg每4小时1次,其中3例因不良反应停药:2例神经病,1例严重关节痛。小剂量时,不良反应发生率明显低于大剂量时,尤其是早期粘膜皮肤并发症很轻,不
Clinical studies have shown that Dideoncytidine (ddC), a reversible transcriptase inhibitor, is a potent anti-human immunodeficiency virus-1 (HIV-1) therapeutic drug. After treatment, the level of circulating HIV-1P24 antigen decreased and the number of CD_4 ~ + lymphocytes increased; however, it could cause severe dose-related neuropathy. Small doses of ddC-related toxicity reported 15 cases of taking ddC0.005mg / kg once every 4 hours, of which 3 were discontinued due to adverse reactions: 2 cases of neuropathy, 1 case of severe joint pain. Small doses, the incidence of adverse reactions was significantly lower than the high dose, especially in early mucosal skin complications are very light, not